Literature DB >> 21186793

Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.

John J Caldwell1, Emma J Welsh, Cornelis Matijssen, Victoria E Anderson, Laurent Antoni, Kathy Boxall, Frederique Urban, Angela Hayes, Florence I Raynaud, Laurent J M Rigoreau, Tony Raynham, G Wynne Aherne, Laurence H Pearl, Antony W Oliver, Michelle D Garrett, Ian Collins.   

Abstract

Structure-based design was applied to the optimization of a series of 2-(quinazolin-2-yl)phenols to generate potent and selective ATP-competitive inhibitors of the DNA damage response signaling enzyme checkpoint kinase 2 (CHK2). Structure-activity relationships for multiple substituent positions were optimized separately and in combination leading to the 2-(quinazolin-2-yl)phenol 46 (IC(50) 3 nM) with good selectivity for CHK2 against CHK1 and a wider panel of kinases and with promising in vitro ADMET properties. Off-target activity at hERG ion channels shown by the core scaffold was successfully reduced by the addition of peripheral polar substitution. In addition to showing mechanistic inhibition of CHK2 in HT29 human colon cancer cells, a concentration dependent radioprotective effect in mouse thymocytes was demonstrated for the potent inhibitor 46 (CCT241533).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186793     DOI: 10.1021/jm101150b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

2.  Protein kinase d as a potential chemotherapeutic target for colorectal cancer.

Authors:  Ning Wei; Edward Chu; Peter Wipf; John C Schmitz
Journal:  Mol Cancer Ther       Date:  2014-03-14       Impact factor: 6.261

Review 3.  DNA repair targeted therapy: The past or future of cancer treatment?

Authors:  Navnath S Gavande; Pamela S VanderVere-Carozza; Hilary D Hinshaw; Shadia I Jalal; Catherine R Sears; Katherine S Pawelczak; John J Turchi
Journal:  Pharmacol Ther       Date:  2016-02-16       Impact factor: 12.310

4.  Autophagy and Apoptosis Specific Knowledgebases-guided Systems Pharmacology Drug Research.

Authors:  Peihao Fan; Nanyi Wang; Lirong Wang
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

Review 5.  DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities.

Authors:  Yasser Abuetabh; H Helena Wu; Chengsen Chai; Habib Al Yousef; Sujata Persad; Consolato M Sergi; Roger Leng
Journal:  Exp Mol Med       Date:  2022-10-07       Impact factor: 12.153

Review 6.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Authors:  Thomas P Matthews; Alan M Jones; Ian Collins
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

Review 7.  Directing the use of DDR kinase inhibitors in cancer treatment.

Authors:  Inger Brandsma; Emmy D G Fleuren; Chris T Williamson; Christopher J Lord
Journal:  Expert Opin Investig Drugs       Date:  2017-10-14       Impact factor: 6.206

Review 8.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors:  Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-11-30       Impact factor: 3.597

9.  Benzimidazole inhibitors of the protein kinase CHK2: clarification of the binding mode by flexible side chain docking and protein-ligand crystallography.

Authors:  Cornelis Matijssen; M Cris Silva-Santisteban; Isaac M Westwood; Samerene Siddique; Vanessa Choi; Peter Sheldrake; Rob L M van Montfort; Julian Blagg
Journal:  Bioorg Med Chem       Date:  2012-09-21       Impact factor: 3.641

10.  Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.

Authors:  M Cris Silva-Santisteban; Isaac M Westwood; Kathy Boxall; Nathan Brown; Sam Peacock; Craig McAndrew; Elaine Barrie; Meirion Richards; Amin Mirza; Antony W Oliver; Rosemary Burke; Swen Hoelder; Keith Jones; G Wynne Aherne; Julian Blagg; Ian Collins; Michelle D Garrett; Rob L M van Montfort
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.